Literature DB >> 7306513

Mechanism of binding of multivalent immune complexes to Fc receptors. 2. Kinetics of binding.

S K Dower, J A Titus, C DeLisi, D M Segal.   

Abstract

The kinetics of association and dissociation of affinity cross-linked IgG oligomers with Fc receptors on P388D1 cells have been studied at 0 degrees C. For dimers prepared with two different affinity cross-linking reagents (DIBADL and BDPE) and also trimers and a heavy oligomer fraction prepared with BDPE, monomeric IgG accelerates the rate of dissociation of bound oligomer from the cells. This observation is consistent with a binding mechanism in which monovalently, and multivalently bound species are in rapid equilibrium with one another on the cell surface and in which the rate of formation of the divalently bound species is faster than the dissociation of the monovalent species from the cells. As predicted, the rates of dissociation of BDPE cross-linked oligomers decrease with size, and dimers (cross-linked with DIBADL) which can self-aggregate on the cell surface dissociate more slowly than nonaggregating (BDPE) dimers. The association and dissociation of oligomers with P388D1 cells proceed by parallel fast and slow processes, even with cells that bind dimers with a single affinity. The origin of this heterogeneity is not known but could arise from a fraction of receptors in environments with limited accessibility to bulk solution. The fast component of the association reaction is second order, and the rate-limiting step of this process is the formation of the monovalently bound intermediate from solution-phase oligomer.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7306513     DOI: 10.1021/bi00525a008

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  10 in total

1.  Equilibrium and kinetic parameters for the interaction of a monoclonal antibody with liposomes bearing fluorescent haptens.

Authors:  A Petrossian
Journal:  Cell Biophys       Date:  1993 Aug-Dec

2.  The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor.

Authors:  M Grell; H Wajant; G Zimmermann; P Scheurich
Journal:  Proc Natl Acad Sci U S A       Date:  1998-01-20       Impact factor: 11.205

3.  Rational engineering of antibody therapeutics targeting multiple oncogene pathways.

Authors:  Jonathan Fitzgerald; Alexey Lugovskoy
Journal:  MAbs       Date:  2011-05-01       Impact factor: 5.857

4.  Characterization of the high-affinity cell-surface receptor for murine B-cell-stimulating factor 1.

Authors:  L S Park; D Friend; K Grabstein; D L Urdal
Journal:  Proc Natl Acad Sci U S A       Date:  1987-03       Impact factor: 11.205

5.  Impact of benzene metabolites on differentiation of bone marrow progenitor cells.

Authors:  R D Irons; W S Stillman
Journal:  Environ Health Perspect       Date:  1996-12       Impact factor: 9.031

6.  Characterization of the cell surface receptor for human granulocyte/macrophage colony-stimulating factor.

Authors:  L S Park; D Friend; S Gillis; D L Urdal
Journal:  J Exp Med       Date:  1986-07-01       Impact factor: 14.307

Review 7.  Critical parameters for design and development of multivalent nanoconstructs: recent trends.

Authors:  Avijit Kumar Bakshi; Tanweer Haider; Rahul Tiwari; Vandana Soni
Journal:  Drug Deliv Transl Res       Date:  2022-01-11       Impact factor: 5.671

8.  Detection and characterization of high affinity plasma membrane receptors for human interleukin 1.

Authors:  S K Dower; S R Kronheim; C J March; P J Conlon; T P Hopp; S Gillis; D L Urdal
Journal:  J Exp Med       Date:  1985-08-01       Impact factor: 14.307

9.  Characterization of the human B cell stimulatory factor 1 receptor.

Authors:  L S Park; D Friend; H M Sassenfeld; D L Urdal
Journal:  J Exp Med       Date:  1987-08-01       Impact factor: 14.307

10.  Murine interleukin 7 (IL-7) receptor. Characterization on an IL-7-dependent cell line.

Authors:  L S Park; D J Friend; A E Schmierer; S K Dower; A E Namen
Journal:  J Exp Med       Date:  1990-04-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.